SCHEMBL42476

SCHEMBL42476

CC(C)(C)OC(=O)N1CCCCC1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
MITF O75030 1/20 0.48
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.41
MAPT P10636 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 2/20 0.40
THRB P10828 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
RECQL P46063 1/20 0.40
BLM P54132 1/20 0.40
USP2 O75604 1/20 0.40
CTSK P43235 1/20 0.39
STAT6 P42226 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5421438 0.98 SMN1; SMN2 (0.50) SMN1; SMN2MITFLMNAHPGDMAPT
SCHEMBL31551856 0.98 SMN1; SMN2 (0.50) SMN1; SMN2MITFLMNAHPGDMAPT
SCHEMBL205421 0.95 LMNA (0.48) SMN1; SMN2MITFLMNAHPGDMAPT
SCHEMBL7495565 0.93 LMNA (0.47) SMN1; SMN2MITFLMNAHPGDMAPT
SCHEMBL513188 0.87 USP2 (0.43) SMN1; SMN2HPGDMAPTKDM4ETHRB
Formic Acid Methyl Ester SCHEMBL27092786 0.85 MAPT (0.41) SMN1; SMN2MITFLMNAHPGDMAPT
SCHEMBL22578666 0.84 CHRM2 (0.37) SMN1; SMN2MITFLMNAHPGDMAPT
SCHEMBL17043059 0.83 MITF (0.43) SMN1; SMN2MITFLMNAMAPTMEN1
SCHEMBL28974037 0.83 LMNA (0.41) SMN1; SMN2LMNAHPGDMAPTMEN1
SCHEMBL5278772 0.81 HPGD (0.40) SMN1; SMN2MITFHPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 759 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119661529-A Synthesis method of 3, 9-diazaspiro [5.5] undecane-3-tert-butyl formate 上海馨远医药科技有限公司 2025-03-21 CN claimed
CN-117658896-A Curcumin-piperlongumin derivative and preparation method and application thereof 温州医科大学 2024-03-08 CN claimed
CN-114277006-B Alcohol dehydrogenase and application thereof in synthesis of chiral heterocyclic alcohol 江南大学 2023-06-06 CN claimed
CN-114277006-A Alcohol dehydrogenase and application thereof in synthesis of chiral heterocyclic alcohol 江南大学 2022-04-05 CN claimed
CN-111116456-B Preparation method of 4, 4-difluoropiperidine hydrochloride 南通华祥医药科技有限公司 2022-01-28 CN claimed
US-20180326407-A1 Olefin polymerization catalyst components and process for the production of olefin polymers therewith FORMOSA PLASTICS CORPORATION, USA 2018-11-15 US claimed
US-10124324-B1 Olefin polymerization catalyst components and process for the production of olefin polymers therewith FORMOSA PLASTICS CORPORATION, USA (US) 2018-11-13 US claimed
WO-2026098613-A1 METHOD FOR PREPARING BENZODIOXOLE OR SALT THEREOF 江苏恒瑞医药股份有限公司 2026-05-15 WO disclosed
EP-4731623-A1 CARBOLINE COMPOUNDS AND USE THEREOF PTC Therapeutics, Inc. (US) 2026-04-29 EP disclosed
EP-4727915-A1 AMIDE CONTAINING LIPIDS Acuitas Therapeutics, Inc. (CA) 2026-04-22 EP disclosed
US-12605450-B2 C3-carbon linked glutarimide Degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2026-04-21 US disclosed
US-12589092-B2 Polycyclic compound acting as kinase inhibitor HANGZHOU INNOGATE PHARMA CO., LTD. (CN) 2026-03-31 US disclosed
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 US disclosed
US-6037341-A HAVING POTENT ANTIMICROBIAL EFFECTS OVER GRAM-POSITIVE BACTERIA AND GRAM-NEGATIVE BACTERIA EISAI CO., LTD. (JP) 2000-03-14 US disclosed
US-5998438-A SEROTONIN RECEPTOR ANTAGONIST; HEADACHE THERAPY ALLELIX BIOPHARMACEUTICALS, INC. (CA) 1999-12-07 US disclosed
EP-0940401-A1 2-CARBONYLTHIAZOLE DERIVATIVES AND USE OF THE SAME TAISHO PHARMACEUTICAL CO. LTD (JP) 1999-09-08 EP disclosed
US-5852049-A Aromatic ethers derived from indoles which are useful as medicaments PIERRE FABRE MEDICAMENT (FR) 1998-12-22 US disclosed
US-5734059-A Production intermediate and process for producing pyridine derivative TAIHO PHARMACEUTICAL CO., LTD. (JP) 1998-03-31 US disclosed
EP-0787724-A1 NOVEL INTERMEDIATE FOR PRODUCTION AND PROCESS FOR PRODUCING PYRIDINE DERIVATIVE TAIHO PHARMACEUTICAL CO., LTD. (JP) 1997-08-06 EP disclosed
EP-0773222-A1 NOVEL CARBAPENEM DERIVATIVE Eisai Co., Ltd. (JP) 1997-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12605450-B2 C3-carbon linked glutarimide Degronimers for target protein degradation NEDD4, UBE3A, UBE3C SMN1; SMN2 3245/4885MITF 4077/4885LMNA 2573/4885
US-12589092-B2 Polycyclic compound acting as kinase inhibitor CDK1, CDK4, CDK2 SMN1; SMN2 2735/4885MITF 1997/4885LMNA 1602/4885
US-20260078117-A1 COMPOUNDS AND METHODS OF USE NR3C2, ADRA1A, CNR1 SMN1; SMN2 1645/4885MITF 2355/4885LMNA 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.